Decitabine vs hydroxyurea for advanced proliferative CMML
Raphael Itzykson, MD, PhD, Saint-Louis Hospital AP-HP, Paris, France, outlines the results of the Phase III Dacota trial (EudraCT 2014-000200-10), investigating decitabine versus hydroxyurea for patients with advanced proliferative chronic myelomonocytic leukemia (CMML). The study found that decitabine did not provide an overall or event-free survival advantage over hydroxyurea. Additionally, Prof. Itzykson highlights that it is feasible to conduct randomized clinical trials in advanced proliferative CMML, which remains an unmet medical need This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
▶︎
CMML: Risk Stratification and Treatment
▶︎
MDS 2023: PS 9 - CMML and Other Specific Sub Types of MDS and MDS/MPN
▶︎
Pharmacokinetic Guided Dosing of Hydroxyurea
▶︎
Ruxolitinib in CMML: Study Shows Promising Results
▶︎
Leukemias: Pathology review
▶︎
Tips for New CML Survivors / Tips for Newly Diagnosed with Chronic Myeloid Leukemia
▶︎
NERVOUS 12-Year-Old Who Can Sing Without Opening Her Mouth Earns Mel B's GOLDEN BUZZER!
▶︎
Sacha 'Borat' Baron Cohen Asks Melanie "What Her Price Is" | Friday Night With Jonathan Ross
▶︎
How To Think SO CLEARLY People Assume You're A Genius
▶︎
Why Returning From Mars Is Impossible: Feynman's Warning
▶︎
Management of Chronic Myeloid Leukemia (CML) in special populations
▶︎
Diagnosis and management of CMML
▶︎
Hydroxyurea in Sickle Cell Disease
▶︎
Long Term Survival Results & Prognostic Factors of Higher Risk MDS/CMML... - G Garcia-Manero
▶︎
Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
▶︎
Chronic myelomonocytic leukemia patient shares why she feels safe at MD Anderson during COVID-19
▶︎
How Do I Know If Hydroxyurea is Not Right for Me?
▶︎
Care and treatment of CMML – Interview with expert Dr Dan Wiseman, The Christie NHS Foundation Trust
▶︎
CMML and other Monocytic Malignancies - Challenges in Diagnosis
▶︎